U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

  • Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
  • Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
  • As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N214622

Product 001
INFIGRATINIB PHOSPHATE (TRUSELTIQ) CAPSULE 25MG

Patent Data

Product No Patent No Patent Expiration Drug Substance Drug Product Patent Use Code Delist Requested Submission Date
001 8552002 08/25/2029 DS DP 06/08/2021
001 9067896 08/06/2028 DS 06/08/2021
001 10278969 12/11/2034 DP 06/08/2021
001 11160804 12/11/2034 DP 12/01/2021

Exclusivity Data

Product No Exclusivity Code Exclusivity Expiration
001 NCE 05/28/2026
001 ODE-353 05/28/2028

 

 


View a list of all patent use codes
View a list of all exclusivity codes

Back to Top